Torsdag 19 Februari | 10:58:24 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

FluoGuide A/S

Bifogade filer

Prenumeration

Kalender

Est. tid*
2026-11-26 07:20 Kvartalsrapport 2026-Q3
2026-08-25 07:20 Kvartalsrapport 2026-Q2
2026-05-27 07:20 Kvartalsrapport 2026-Q1
2026-03-25 N/A Årsstämma
2026-02-25 07:00 Bokslutskommuniké 2025
2025-11-27 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-28 - Kvartalsrapport 2025-Q1
2025-03-28 - X-dag ordinarie utdelning FLUO 0.00 DKK
2025-03-27 - Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag ordinarie utdelning FLUO 0.00 DKK
2024-03-20 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-29 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-03-22 - X-dag ordinarie utdelning FLUO 0.00 DKK
2023-03-21 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-19 - X-dag ordinarie utdelning FLUO 0.00 DKK
2022-05-18 - Årsstämma
2022-03-30 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-26 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning FLUO 0.00 DKK
2021-02-26 - Bokslutskommuniké 2020
2021-02-09 - Årsstämma
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-14 - Kvartalsrapport 2020-Q2
2020-05-27 - Kvartalsrapport 2020-Q1
2020-04-09 - X-dag ordinarie utdelning FLUO 0.00 DKK
2020-04-08 - Årsstämma
2020-02-28 - Bokslutskommuniké 2019
2019-11-29 - Kvartalsrapport 2019-Q3
2019-05-31 - Kvartalsrapport 2019-Q1

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
FluoGuide är ett danskt bolag verksamt inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar mot olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Invitation to FluoGuide A/S (Nasdaq: FLUO) live webcast on 25 February 2026
2026-02-19 09:16:00

FluoGuide A/S will publish its Annual Report 2025 on Wednesday, 25 February 2026.

Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company’s 2025 financial results, strategic progress and expectations for 2026 in a live webcast. The webcast is hosted by BioStock. The presentation will be followed by a live Q&A session, where questions can be asked during the event or submitted in advance by e-mail to redaktion@biostock.se.

Date: Wednesday 25 February 2026
Time: 14.00 CET

Please login to the webcast via the following link: https://www.youtube.com/live/DlK74aNE86M
Questions can be sent in advance by email to redaktion@biostock.se or can be raised at the question session during the webcast.
A recorded version of the presentation will be available on FluoGuide’s website after the webcast.
 

For further information, please contact:
Morten Albrechtsen, CEO
FluoGuide A/S
Phone: +45 24 25 62 66
E-mail: ma@fluoguide.com

Certified Adviser:
Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se

Follow FluoGuide on linkedIn
Follow FluoGuide on LinkedIn: https://www.linkedin.com/company/fluoguide/

Sign up to receive FluoGuide news
Sign up to receive FluoGuide news: https://fluoguide.com/investor/email-alerts/

About FluoGuide
FluoGuide lights up cancer to maximize surgical outcomes in oncology. FluoGuide’s lead product, FG001, is designed to improve surgical precision by lighting up cancer intraoperatively. The improved precision has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision enhances the likelihood of complete cure and lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated in several phase II clinical trials. The lead indications of FG001 are aggressive brain cancer (glioblastoma) and oral head and neck cancer. FluoGuide has entered partnerships with leading MedTech companies with the aim of accelerating development and commercialization. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.

For more information on FG001 or FluoGuide’s uPAR technology platform, please visit our home page www.fluoguide.com

Attachments
Invitation to FluoGuide A/S (Nasdaq: FLUO) live webcast on 25 February 2026

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden